Granules India's fourth-quarter profit jumps on strong demand

Granules India

29/04/2026 08:48

April 29 (Reuters) - Drugmaker Granules India GRAN.NS reported a 32.6% jump in fourth-quarter profit on Wednesday, driven by recent portfolio additions and robust demand for paracetamol and methocarbamol in its major markets.

Here are the details:

Consolidated profit rose to 2.02 billion rupees ($21.3 million) for the quarter ended March 31, from 1.52 billion rupees a year earlier.

Managing Director and Chairman Krishna Chigurupati said, "We delivered a strong performance in Q4 FY26, driven by continued portfolio expansion, disciplined execution, and steady progress across regulatory, compliance, and sustainability initiatives."

Revenue from operations climbed about 23% to 14.71 billion rupees, supported by a 12% increase in North America, which accounts for about two-thirds of the company's sales.

"North America continued to anchor the business as the core growth engine, (while) Europe emerged as a high-momentum market with near doubling performance," the company said.

Shares of the company rose 2% in afternoon trading.

Granules accounts for about 30% of the global paracetamol market and operates 10 manufacturing plants worldwide - seven in India, two in the U.S. and one in Europe.

The company sells its products globally, including in the United States, Canada, Latin America, Europe, the Asia-Pacific region and India.

Analysts at Emkay Global said growth in fiscal 2027 is likely to be driven by the ramp-up of recent product launches, while additional controlled drug products slated  to be introduced from fiscal 2028 should support longer-term growth.

The company has demonstrated stronger-than-expected margin resilience over the past six quarters despite regulatory issues at its flagship Gagillapur facility, the analysts added.

Granules has increased oversight at its manufacturing facilities after the U.S. Food and Drug Administration flagged violations, including record-keeping lapses and contamination control issues, at its largest plant.

($1 = 94.7450 Indian rupees)

 (Reporting by Abhinav Parmar in Bengaluru; Editing by Sumana Nandy)

 ((Abhinav.Parmar@thomsonreuters.com;))